Skip to main content
. 2022 Apr 25;27(6):441–446. doi: 10.1093/oncolo/oyac075

Figure 1.

Figure 1.

Real-world progression-free survival. CDK, cyclin-dependent kinases 4/6 inhibitors; Chemo, cytotoxic chemotherapy; F, fulvestrant; mTOR, mammalian target of rapamycin inhibitor (everolimus). “Other” includes endocrine therapies, various targeted therapies, trial drugs, etc. that do not fit into any of the other 4 categories.